Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Usama Daimee

Clinical Cardiac Electrophysiology Dallas, TX Medical Doctor

NPI 1003259607 CMS profile 6413631

221 W. Colorado Blvd., Pavilion II Suite 831, Dallas, TX 75208

Open in the dashboard

General payments

$102,045

709 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Usama Daimee of Dallas, TX is reported in the CMS Open Payments database as having received $102,045 across 709 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,113 102
2024 General $26,697 194
2023 General $29,425 196
2022 General $27,295 184
2021 General $3,492 31
2019 General $23 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Usama Daimee
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Usama Daimee were reported at $15,113. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Usama Daimee Clinical Cardiac Electrophysiology median Middle half National median
2019 $23 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $3,492 $1,185 $326–$4,739 $132
2022 $27,295 $2,073 $554–$6,789 $149
2023 $29,425 $2,568 $759–$8,159 $160
2024 $26,697 $2,557 $703–$7,403 $164
2025 $15,113 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $43,473 267 payments
  2. Medtronic, Inc. $21,356 195 payments
  3. Boston Scientific Corporation $13,648 73 payments
  4. Medical Device Business Services, Inc. $13,610 70 payments
  5. Philips Electronics North America Corporation $3,761 30 payments
  6. Biotronik Inc. $2,345 13 payments
  7. Biosense Webster, Inc. $1,746 37 payments
  8. Cook Medical LLC $533 4 payments
  9. Baylis Medical Company Inc $532 6 payments
  10. Cook Incorporated $424 2 payments
  11. Other $618 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $72,182 325 payments
  2. Food and Beverage $21,941 373 payments
  3. Grant $6,400 3 payments
  4. Education $1,522 8 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $15,606 110 payments
  2. ENSITE PRECISION $13,561 106 payments
  3. ENSITE Electrophysiology $9,934 57 payments
  4. VersaCross Access Solution $4,813 26 payments
  5. ENSITE Structural Heart $4,341 28 payments
  6. Micra $3,090 34 payments
  7. AVEIR Cardiac Rhythm Management $2,584 8 payments
  8. (9124) LM Undivided $2,472 19 payments
  9. AVEIR Structural Heart $2,277 13 payments
  10. EMBLEM MRI S-ICD $2,151 12 payments
  11. Other $19,520 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

132

Median for Cardiology: 2,533

Drug cost

$25,905

Median for Cardiology: $485,213

Branded share of claims

21.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 28 $24,459
Metoprolol Succinate Generic 59 $832
Amiodarone Hcl Generic 33 $577
Carvedilol Generic 12 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$43,268

Medicare's payments for the services billed

Medicare patients

305

Average age 74

Services billed

541

134 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Atrial fibrillation 56%
Arthritis 56%
Heart failure 44%
Diabetes 39%
Chronic kidney disease 31%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

709 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record